Literature DB >> 22926290

Mitochondria in relation to cancer metastasis: introduction to a mini-review series.

Peter L Pedersen1.   

Abstract

This introductory article and those that follow focus on the roles that mitochondria may have in cancer metastasis (spreading) that all too frequently leads to death of cancer patients. The history of cancer dates back in time to several thousand years BC and continues to this day. Although billions of dollars have been invested, numerous cancer researchers/scientists and oncologist located at universities, hospitals, cancer centers, commercial entities (companies), and government agencies have been unable to discover "magic bullets" to quickly silence most cancers. That is, agents that are effective not only in eradicating the primary tumor at its site of origin, but eradicating also distant tumors that have arisen therefrom via metastatic cells. Fortunately, in recent years some researchers have obtained evidence that the mitochondria of cancer cells are involved not only in providing in part the necessary energy (ATP) to fuel their growth, but hold the secrets to their immortality, and propensity to metastasize (spread) from their original site of origin to other body locations. This introductory article, as well as those that follow, focus on the possible roles of mitochondria in cancer metastasis as well as strategies to arrest cancer metastasis based on this knowledge. Ideally, for a patient to become "cancer free" the anticancer agent/agents used must 1) eradicate the primary tumor at its site of origin, 2) eradicate any tumors at other body locations that have arisen via metastasis, and 3) eradicate any tumor cells that remain in the blood, i.e., circulating tumor cells. One such agent that holds promise for doing all three is the small molecule 3-bromopyruvate (3BP) discovered in the author's laboratory by Dr. Young H. Ko near the turn of the century to be a potent anti-cancer agent [Ko et al.(2001) Can Lett 173:83-91].

Entities:  

Mesh:

Year:  2012        PMID: 22926290     DOI: 10.1007/s10863-012-9470-z

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  15 in total

1.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

2.  Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line.

Authors:  R A Nakashima; M G Paggi; L J Scott; P L Pedersen
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

Review 3.  Mitochondria in relation to cancer metastasis.

Authors:  Bidur Bhandary; Anu Marahatta; Hyung-Ryong Kim; Han-Jung Chae
Journal:  J Bioenerg Biomembr       Date:  2012-12       Impact factor: 2.945

Review 4.  Mitochondrial dysfunction and cancer metastasis.

Authors:  Emily I Chen
Journal:  J Bioenerg Biomembr       Date:  2012-12       Impact factor: 2.945

Review 5.  Regulation of metastasis; mitochondrial DNA mutations have appeared on stage.

Authors:  Kaori Ishikawa; Hirotake Imanishi; Keizo Takenaga; Jun-Ichi Hayashi
Journal:  J Bioenerg Biomembr       Date:  2012-12       Impact factor: 2.945

Review 6.  Targeting proteomics to investigate metastasis-associated mitochondrial proteins.

Authors:  Hsiu-Chuan Chou; Hong-Lin Chan
Journal:  J Bioenerg Biomembr       Date:  2012-12       Impact factor: 2.945

7.  High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase.

Authors:  E Bustamante; P L Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

8.  Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding.

Authors:  E Bustamante; H P Morris; P L Pedersen
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

9.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

10.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

Authors:  Young H Ko; Barbara L Smith; Yuchuan Wang; Martin G Pomper; David A Rini; Michael S Torbenson; Joanne Hullihen; Peter L Pedersen
Journal:  Biochem Biophys Res Commun       Date:  2004-11-05       Impact factor: 3.575

View more
  3 in total

Review 1.  The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Authors:  J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal
Journal:  J Bioenerg Biomembr       Date:  2016-07-25       Impact factor: 2.945

Review 2.  Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism.

Authors:  Balaraman Kalyanaraman
Journal:  Redox Biol       Date:  2017-04-13       Impact factor: 11.799

3.  Identification and validation of a signature involving voltage-gated chloride ion channel genes for prediction of prostate cancer recurrence.

Authors:  Yong Luo; Xiaopeng Liu; Xiaoxiao Li; Weide Zhong; Jingbo Lin; Qingbiao Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.